Summary
Results from ABSORB II [Serruys PW et al. Lancet. 2014], the first study to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent, demonstrated similar 1-year clinical outcomes in patients with coronary artery disease.
- Coronary Artery Disease
- Cardiology Clinical Trials
- Interventional Techniques & Devices
- Coronary Artery Disease
- Cardiology Clinical Trials
- Cardiology
- Interventional Techniques & Devices
- © 2014 MD Conference Express®
Tools
ABSORB II: Comparable Clinical Outcomes Noted with ABSORB Scaffold and XIENCE Stents
Permalink:
